-
Media Release
Novartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch My Home In Sight, A Program Empowering People With Wet AMD To Live More Independently At Home
-
Media Release
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
-
Media Release
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
-
Media Release
Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions
-
Media Release
Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions
-
Media Release
Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®
-
Media Release
Long-term Survival Benefit Shown for Metastatic Melanoma Patients Treated with Novartis Tafinlar® + Mekinist®
-
Media Release
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
-
Media Release
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
-
Media Release
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
-
Media Release
AveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
-
Media Release
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families